



## Clinical trial results:

## MAGnetic versus STandard technique for sentinel node biopsy in breast cancer compared in a Randomised controlled trial

### Summary

EudraCT number	2015-000549-21
Trial protocol	GB
Global end of trial date	20 February 2017

### Results information

Result version number	v1
This version publication date	04 October 2019
First version publication date	04 October 2019
Summary attachment (see zip file)	Cancelled Before Active Statement (Cancelled before Active Statement.pdf)

### Trial information

#### Trial identification

Sponsor protocol code	MAGSTAR
-----------------------	---------

#### Additional study identifiers

ISRCTN number	ISRCTN20200149
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	U1111-1164-0844
Other trial identifiers	Trialregister.nl (Dutch registration): Pending

Notes:

#### Sponsors

Sponsor organisation name	King's College London
Sponsor organisation address	The Strand, London, United Kingdom, WC2R 2LS
Public contact	Mr Michael Douek, King's College London, 44 2071886380, michael.douek@kcl.ac.uk
Scientific contact	Mr Michael Douek, King's College London, 44 2071886380, michael.douek@kcl.ac.uk
Sponsor organisation name	Guy's & St Thomas' NHS Foundation Trust
Sponsor organisation address	F16 Tower Wing, Guy's Hospital, Great Maze Pond, London, United Kingdom, SE19RT
Public contact	Mr Michael Douek, Guy's and St Thomas' NHS Foundation Trust, 44 2071886380, michael.douek@kcl.ac.uk
Scientific contact	Mr Michael Douek, Guy's and St Thomas' NHS Foundation Trust, 2071885732 2071886380, michael.douek@kcl.ac.uk

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No	No

1901/2006 apply to this trial?
--------------------------------

Notes:

### Results analysis stage

Analysis stage	Final
Date of interim/final analysis	20 February 2017
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	20 February 2017
Was the trial ended prematurely?	No

Notes:

### General information about the trial

Main objective of the trial:

To determine whether the magnetic technique (involving the magnetic tracer and magnetometer) can be used instead of the standard 'dual' technique (blue dye and radioactive injection) to locate lymph nodes during breast cancer surgery.

Protection of trial subjects:

N/A

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	20 February 2017
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

### Population of trial subjects

#### Subjects enrolled per country

Country: Number of subjects enrolled	United Kingdom: 99999
Worldwide total number of subjects	99999
EEA total number of subjects	99999

Notes:

#### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	99999
From 65 to 84 years	0

85 years and over	0
-------------------	---

## Subject disposition

### Recruitment

Recruitment details:

99999 is "Not applicable" value or 0 participants, this trial was discontinued with no participants enrolled in the trial

### Pre-assignment

Screening details:

N/A

### Period 1

Period 1 title	Overall Trial (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Blinding implementation details:

N/A

### Arms

Arm title	Nanocoll
-----------	----------

Arm description:

Nanocoll 0.3 ml

Arm type	Experimental
Investigational medicinal product name	Nanocoll
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Dosage would have been one injection 0.3 ml subcutaneously

<b>Number of subjects in period 1</b>	Nanocoll
Started	99999
Completed	99999

## Baseline characteristics

### Reporting groups

Reporting group title

Overall Trial

Reporting group description: -

Reporting group values	Overall Trial	Total	
Number of subjects	99999	99999	
Age categorical			
Units: Subjects			
In utero		0	
Preterm newborn infants (gestational age < 37 wks)		0	
Newborns (0-27 days)		0	
Infants and toddlers (28 days-23 months)		0	
Children (2-11 years)		0	
Adolescents (12-17 years)		0	
Adults (18-64 years)		0	
From 65-84 years		0	
85 years and over		0	
Age continuous			
Units: years			
arithmetic mean	0		
standard deviation	± 0	-	
Gender categorical			
Units: Subjects			
Female	99999	99999	
Male	0	0	

## End points

### End points reporting groups

Reporting group title	Nanocoll
Reporting group description: Nanocoll 0.3 ml	

### Primary: Overall SLNB identification rate

End point title	Overall SLNB identification rate <sup>[1]</sup>
End point description: 99999 is "Not applicable" value or 0 participants, this trial was discontinued with no participants enrolled in the trial.	
End point type	Primary
End point timeframe: N/A	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No subjects were enrolled in the trial hence results are not available

End point values	Nanocoll			
Subject group type	Reporting group			
Number of subjects analysed	99999 <sup>[2]</sup>			
Units: 0				
number (not applicable)	99999			

Notes:

[2] - No subjects were enrolled in the trial hence results are not available

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information<sup>[1]</sup>

Timeframe for reporting adverse events:

All adverse events occurring during the course of the clinical trial were to be collected.

Adverse event reporting additional description:

N/A

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	0
--------------------	---

### Reporting groups

Reporting group title	Nanocoll
-----------------------	----------

Reporting group description:

Nanocoll 0.3 ml

Serious adverse events	Nanocoll		
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 99999 (0.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Nanocoll		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	0 / 99999 (0.00%)		

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: No subjects were enrolled in the trial hence results are not available

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

99999 is "Not applicable" value or 0 participants, this trial was discontinued with no participants enrolled in the trial.
--

Notes: